[Hypotensive and anti-ischemic efficiency of estulic in course treatment of myocardial infarction complicated by essential hypertension].
OBJECTIVE
To assess hypotensive and antiischemic activity of estulik (Sandos, Switzerland) in patients with myocardial infarction (MI) complicated by essential hypertension (EH).


METHODS
23 MI patients with moderate EH (diastolic blood pressure up to 110 mm Hg) and 25 patients with manifest EH (diastolic blood pressure 115-120 mm Hg) of group 1 and 2, respectively, have received single doses and a 10-day course of estulik in a dose 0.5-1.0 mg/day. Hemodynamic and antiischemic activities were evaluated at echocardiography, coupled veloergometry, Holter monitoring, myocardial scintigraphy, polarography. In 31% of the patients selective coronarography was made.


RESULTS
Clinical condition and hemodynamics of group 1 patients have improved by 30-40%, microcirculation has improved by 25-35%. In group 2 patients the drug was found ineffective.


CONCLUSIONS
Estulik is a drug of choice in moderate EH with manifest angina pectoris.
Tepliakov
A T
AT
Braslavskaia
T G
TG
Alugishvili
M Z
MZ
Karpov
R S
RS
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects*; D004452:Echocardiography; D015716:Electrocardiography, Ambulatory; D005080:Exercise Test; D016316:Guanfacine / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010101:Oxygen Consumption / Q000187:drug effects; D011048:Polarography; D015635:Radionuclide Ventriculography; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D016316:Guanfacine